ResMed lifts September quarter profit by 14%
ResMed (ASX:RMD) grew its September quarter profit 14% to US$80.9 million ($84.4 million) on the back of a 5% increase in revenue.
Revenue for the quarter reached US$357.7 million ($373.1 million), with the growth driven by sales of the sleep-disordered breathing treatment device company’s higher-valued flow generators.
Sales from the Americas increased 4% to US$201.5 million, while revenue from outside the region were up 5%.
R&D expenses increased 1% to US$27.4 million, but without the positive impact of the depreciation of the Australian dollar, R&D costs would have increased 9%.
ResMed CEO Mick Farrell said the company has been encouraged by early sales of its recently released new mask products, including its Quattro Air, which is on track to being its best mask launch ever.
But he added that the company “continued to face a tough competitive product cycle this quarter”.
The ResMed board has declared a quarterly dividend of $0.25 per share for the company’s NYSE-listed common stock, and an equivalent sum in Australian dollars for its ASX-listed CDI holders, based on exchange rates and the 10:1 CDI-to-share ratio.
ResMed (ASX:RMD) CDIs were trading 1.29% lower at $5.34 as of around 1 pm on Monday.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
